Literature DB >> 8327146

Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease.

S Shimohama1, M Narita, H Matsushima, J Kimura, M Kameyama, M Hagiwara, H Hidaka, T Taniguchi.   

Abstract

We assessed the amount of protein kinase C (PKC) in samples from postmortem normal human and Alzheimer's disease (AD) brains by a two-site enzyme immunoassay that quantitatively identified types alpha, beta, and gamma isozymes. In the normal human brain matter, type beta was the main type present, the majority of each isozyme of PKC being present in the membranous fraction of the brain tissues. In AD brains, the amount of type beta PKC was significantly reduced in the membranous fraction of the temporal cortical tissues. The amounts of types alpha and gamma in the membranous fraction and types alpha, beta, and gamma in the cytosolic fraction in AD brains were lower than in the control brains, but the difference was not significant. There was also a significant decrease in the levels of PKC in the membranous fraction of AD brains, as measured by radioactive phorbol ester binding. These results suggest that the type beta PKC isozyme is mainly present in the human temporal cortex and that reduced levels of type beta PKC in the membranous fraction may reflect a biochemical deficit related specifically to the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8327146     DOI: 10.1212/wnl.43.7.1407

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  Protein kinase C: a family of isoenzymes with distinct roles in pathogenesis.

Authors:  J M Lord; J Pongracz
Journal:  Clin Mol Pathol       Date:  1995-04

Review 2.  Age-related alteration of PKC, a key enzyme in memory processes: physiological and pathological examples.

Authors:  A Pascale; S Govoni; F Battaini
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

3.  Alzheimer's-specific effects of soluble beta-amyloid on protein kinase C-alpha and -gamma degradation in human fibroblasts.

Authors:  A Favit; M Grimaldi; T J Nelson; D L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  NEUROBIOLOGY OF ADULT AND TEENAGE SUICIDE.

Authors:  Ghanshyam N Pandey
Journal:  Asian J Psychiatr       Date:  2011-03-01

Review 5.  Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease.

Authors:  Russell H Swerdlow
Journal:  Antioxid Redox Signal       Date:  2011-09-15       Impact factor: 8.401

Review 6.  Ionic and signal transduction alterations in Alzheimer's disease: relevance of studies on peripheral cells.

Authors:  R Etcheberrigaray; S Bhagavan
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

Review 7.  Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy.

Authors:  L W Jin; T Saitoh
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

Review 8.  Biological basis of suicide and suicidal behavior.

Authors:  Ghanshyam N Pandey
Journal:  Bipolar Disord       Date:  2013-06-15       Impact factor: 6.744

9.  Searching for disease modifiers-PKC activation and HDAC inhibition - a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress.

Authors:  Alan P Kozikowski; Yihua Chen; Tapadar Subhasish; Nancy E Lewin; Peter M Blumberg; Zhenyu Zhong; Melissa A D'Annibale; Weng-Long Wang; Yong Shen; Brett Langley
Journal:  ChemMedChem       Date:  2009-07       Impact factor: 3.466

10.  Inhibition of PKCδ reduces amyloid-β levels and reverses Alzheimer disease phenotypes.

Authors:  Ying Du; Yingjun Zhao; Chuan Li; Qiuyang Zheng; Jing Tian; Zhuyi Li; Timothy Y Huang; Wei Zhang; Huaxi Xu
Journal:  J Exp Med       Date:  2018-05-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.